BioSpace News Archive

Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, will release its 2019 fourth quarter and year-end financial results on Thursday, March 19, 2020, after the close of the U.S. financial markets.

TRACON Pharmaceuticals announced today that it has submitted a request for a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss the trial

Exagen Inc. today announced that it has entered into a strategic partnership with Sonora Quest, the nation’s largest integrated laboratory system. The agreement provides preferred access through Sonora Quest in Arizo

Fluidigm Corporation announced that a consortium of medical schools led by the Icahn School of Medicine at Mount Sinai is utilizing Fluidigm® microfluidics technology to create an epigenetic test for early detection of the novel coronavirus that causes COVID-19.

GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. today announced that it has dosed the first patient in its KIK-AS ( K nockdown of UBE3A -antisense i n K ids with A ngelman S yndrome ) study of GTX-102, an experimental antisense oligonucleotide being evalu

Merck KGaA invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual event

Exceeds 2019 metrics with 166 REMS-certified facilities and 148 formulary approvals through December 31, greater than the year-end goals of 125 for each

AcelRx to acquire Tetraphase in a stock for stock transaction

Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of immunoassay, molecular, and blood chemistry diagnostic testing solutions, today announced that it has received FDA-clearance for Meridian’s new Curian™ and Curian™ HpSA® assay.